Results 11 to 20 of about 2,584,335 (201)
HDL genes & HDL drugs
, 2011 Menno Vergeer onderzocht de genetische basis van het menselijk HDL-cholesterolmetabolisme door middel van familieonderzoek en genetische associatiestudies in grote cohorten.Vergeer, A.M.H.core +5 more sourcesHDL and atherosclerosis : insights from inherited HDL disorders
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014 Plasma high density lipoproteins (HDL) comprise a highly heterogeneous family of lipoprotein particles, differing in density, size, surface charge, and lipid and protein composition.BERNINI, Franco, L. Calabresi, G. Franceschini, F. Bernini, Calabresi L, Simonelli S, M. Gomaraschi, S. Simonelli, Gomaraschi M, Franceschini G. +9 morecore +4 more sourcesHDL concentration, lipid transfer to HDL, and HDL size in normolipidemic nonobese menopausal women
International Journal of Gynecology & Obstetrics, 2009 Objective: To determine the impact of menopause on lipid transfer from donor lipoproteins to high-density lipoproteins (HDLs)-a process that is related to the protective function of HDL-and the size of HDL particles. Method: Plasma from 22 prernenopausal MELO, Nilson R., MARANHAO, Raul C., Arícia H. Giribela, GIRIBELA, Aricia H., Maria C. Latrilha, Edmundo C. Baracat, BARACAT, Edmundo C., Nilson R. Melo, LATRILHA, Maria C., Raul C Maranhão +9 morecore +3 more sourcesHDLs in crises [PDF]
Current Opinion in Lipidology, 2016 The clinical utility of HDLs has been scrutinized upon the publication of Mendelian randomization studies showing no effect of HDL-cholesterol (HDL-C) modifying variants on cardiovascular disease (CVD) outcome. The failures of randomized controlled HDL-C-directed intervention trials have further fueled this skepticism. This general criticism originates Arnold von Eckardstein, Lucia Rohreropenaire +3 more sourcesArginine-directed glycation and decreased HDL plasma concentration and functionality [PDF]
, 2014 Background/Objectives: Decreased plasma concentration of high-density lipoprotein cholesterol (HDL-C) is a risk factor linked to increased risk of cardiovascular disease (CVD). Decreased anti-atherogenic properties of HDL are also implicated in increased Rabbani, Naila, Smith, L., Godfrey, L. (Lisa), Thornalley, Paul J., Yamada-Fowler, N. (Naomi) +4 morecore +1 more sourceLarge-Scale Candidate Gene Analysis of HDL Particle Features [PDF]
, 2011 Background: HDL cholesterol (HDL-C) is an established marker of cardiovascular risk with significant genetic determination. However, HDL particles are not homogenous, and refined HDL phenotyping may improve insight into regulation of HDL metabolism.Burton Paul R., Nelson, CP, Samani, NJ, Nelson, Christopher P, Kalbitzer Hans Robert, Robert Hardwick (232391), Nilesh J. Samani, Braund, P. S., Daniel I Chasman, Fischer Marcus, Rafelt Suzanne, Tobin, MD, Hengstenberg, Christian, Samani Nilesh J., Samani, Nilesh J, Bernhard M Kaess, Christopher P. Nelson (7625975), Rafelt, Suzanne, Stark, K, Nelson Christopher P., Peter S. Braund (7588463), Rafelt, S, Rose, LM, Robert Hardwick, Fischer, Marcus, Clarke, R, Christian Hengstenberg (44258), Suzanne Rafelt, Burton, Paul R, Stark Klaus, Maciej Tomaszewski, Kaess Bernhard M., Samani, Nilesh J., Jemma Hopewell (232402), Hardwick, R., Werner Kremer, Suzanne Rafelt (232388), Debiec, R, Nilesh J. Samani (7579793), Tobin, Martin D, Marcus Fischer (44253), Burton, Paul R., Burton, PR, Debiec Radoslaw, Tomaszewski, Maciej, Kaess, BM, Hopewell Jemma, Nelson, Christopher P., Kremer, Werner, Tomaszewski, M, Paul R. Burton (7581164), Huber, F, Martin D. Tobin, Paul R. Burton, Kremer Werner, Debiec, Radoslaw, Braund Peter S., Radoslaw Debiec (232393), Kaess, Bernhard M, Rose, Lynda M, Hardwick, Robert, Kremer, W, Martin D Tobin, Stark, Klaus, Kaess, Bernhard M., Tomaszewski, Maciej; id_orcid, Kalbitzer, Hans Robert, Maciej Tomaszewski (232381), Rose, Lynda M., Tobin Martin D., Hengstenberg, C, Rose Lynda M., Stark, K., Bernhard M. Kaess (7645556), Chasman, DI, Paul R, Hardwick, R, Robert Clarke (17961), Klaus Stark, Christopher P. Nelson, Tomaszewski Maciej, Hopewell, J, Nelson, C. P., Hans Robert Kalbitzer, Chasman, Daniel I, Peter S Braund, Lynda M. Rose, Hardwick Robert, Kaess, B. M., Paul R Burton, Peter S. Braund, Lynda M Rose, Daniel I. Chasman (7688885), Clarke, Robert, Tomaszewski, M., Hengstenberg Christian, Christopher P Nelson, Radoslaw Debiec, Braund, Peter S., Rafelt, S., Fischer, M, Jemma Hopewell, Chasman Daniel I., Werner Kremer (20876), Martin D. Tobin (7581161), Robert Clarke, Huber, Fritz, Debiec, R., Klaus Stark (44247), Fritz Huber (232395), Lynda M. Rose (7688882), Tobin, Martin D., Marcus Fischer, Clarke Robert, Chasman, Daniel I., Christian Hengstenberg, Braund, PS, Daniel I. Chasman, Fritz Huber, Nilesh J Samani, Braund, Peter S, Hopewell, Jemma, Huber Fritz, Bernhard M. Kaess, Hans Robert Kalbitzer (20878), Kalbitzer, HR +125 morecore +1 more sourceEffects of dalcetrapib in patients with a recent acute coronary syndrome [PDF]
, 2012 In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events.Chaitman Bernard R., Nicholls, Stephen J., Mundl, Hardi,, Ballantyne, Christie M,, Nicholls, Stephen J,, Ballantyne, Christie M., Shah, P.K., Ballantyne Christie M., Ballantyne C.M., Chaitman B.R., Wright, R Scott,, McMurray, J.J.V., McMurray, John J V, Mundl, H., Abt Markus, Shah, Prediman K., Schwartz, G.G., McMurray, John J. V., Leiter, Lawrence A,, Leiter, Lawrence A., Barter, Philip J., DE CATERINA, Raffaele, Tardif, Jean-Claude,, Barter, P.J., Leiter L.A., McMurray, J., Brumm, J., Wright, R Scott, Olsson, A.G., Abt, Markus,, Shah Prediman K., dal OUTCOMES Investigators, Leitersdorf, E., Ballantyne, C.M., Kallend, David,, Brumm, Jochen, Mundl Hardi, Shah, Prediman K,, Holme, Ingar M., McMurray, John J V,, Holme, Ingar M,, Brumm Jochen, McMurray J.J., Kallend, David, Goldner, David, Wright, R., Tardif, J., Chaitman, Bernard R,, Wright R. Scott, Shah, P., Chaitman, Bernard R., Chaitman, B., Kallend David, Nicholls, Stephen J, Schwartz Gregory G., Barter, Philip J,, Leiter Lawrence A., Tardif, Jean-Claude, Barter P.J., Barter, P., Abt, Markus, Schwartz, Gregory G., Leiter, Lawrence A, Holme I.M., Olsson, A., The dal-OUTCOMES Investigators, Tardif Jean Claude, Holme, Ingar M, Leitersdorf, Eran, Wright, R.S., Barter Philip J., Schwartz, Gregory G,, Olsson Anders G., Leiter, L.A., Olsson A.G., Olsson, Anders G., Schwartz, Gregory G, Colquhoun, David, Leiter, L., Nicholls, S.J., Barter, Philip J, Chaitman, Bernard R, Brumm, Jochen,, Leitersdorf E., Nicholls, S., Chaitman, B.R., Holme, I.M., Holme, I., Kallend, D., Brumm J., Mundl, Hardi, Shah, Prediman K, Nicholls Stephen J., Wright, R. Scott, McMurray John J. V., Kallend D., Olsson, Anders,, Ballantyne, C., Holme Ingar M., Olsson, Anders G, Abt M., Schwartz G.G., Leitersdorf Eran, Abt, M., Ballantyne, Christie M, Schwartz, G., Leitersdorf, Eran,, GOLINO, Paolo +107 morecore +1 more sourceHDL [PDF]
Journal of the American Society of Nephrology, 2016 Decades of epidemiologic studies have firmly established the inverse relationship between HDL-cholesterol (HDL-C) levels and cardiovascular events.[1][1] However, the resulting hypothesis that raising HDL-C levels should reduce cardiovascular disease (CVD) has been called into question by ...Valentina, Kon, MacRae F, Lintonopenaire +2 more sourcesHDL – Quo vadis
DMW - Deutsche Medizinische Wochenschrift, 2023 Many epidemiological studies found low plasma levels of high-density lipoprotein (HDL) cholesterol (HDL-C) associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). In cell culture and animal models, HDL particles show many anti-atherogenic actions.von Eckardstein, Arnold, März, Winfried, Laufs, Ulrich +2 moreopenaire +2 more sources
